The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Open accessAbstract
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse. These results suggest that ctDNA MRD could identify candidates for adjuvant therapy and measure response to such treatment. Importantly, factors such as assay type, amount of ctDNA release, and technical and biological background can affect ctDNA MRD results. Furthermore, the clinical utility of ctDNA MRD for treatment personalization remains to be fully established. Here, we review the evidence supporting the value of ctDNA MRD in solid cancers and highlight key considerations in the application of this potentially transformative biomarker.Significance: ctDNA analysis enables detection of MRD and predicts relapse after definitive treatment for solid cancers, thereby promising to revolutionize personalization of adjuvant and consolidation therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a growing body of data demonstrating numerous clinical applications for ctDNA in adults with solid tumors, ranging from prognostication and evaluation of minimal residual disease (MRD) to detection of targetable alterations.7–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [7]
In the citing paper
“although its clinical utility for directing treatment escalation or de-escalation remains under prospective evaluation [ 9 , 10 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Across early-stage solid tumors, postoperative or post-treatment ctDNA detection is consistently associated with a higher risk of recurrence”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“ctDNA analysis has developed most rapidly in common epithelial malignancies, where it is now used for selected advanced-cancer genotyping scenarios and is being actively evaluated for MRD and molecular relapse monitoring after curative-intent therapy [ 5 , 9 , 10 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“In early-stage solid tumors, ctDNA detection after curative-intent therapy has shown strong clinical validity for predicting future relapse”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Among liquid-biopsy analytes, ctDNA is currently the most clinically mature for sarcoma monitoring because it can capture tumor-specific genomic and epigenomic alterations through a minimally invasive and repeatable blood test [ 5 , 9 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“MRD detection requires greater analytical sensitivity than baseline genotyping or advanced-disease resistance monitoring, because tumor-derived DNA may represent only a very small fraction of total cell-free DNA after definitive therapy [ 5 , 9 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Tumor-informed assays can improve sensitivity by tracking patient-specific alterations identified from tissue sequencing”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“whereas tumor-naïve approaches may be useful when tissue is unavailable or when methylation, fragmentomic, or copy-number signals provide sufficient discriminatory power [ 9 , 10 , 11 , 12 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“MRD detection is the most clinically ambitious use of ctDNA in sarcoma. It requires substantially greater analytical sensitivity than baseline genotyping because tumor-derived DNA may be present at very low levels after surgery or definitive therapy [ 5 , 9 , 10 , 11 , 12 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Tumor-informed assays can track multiple patient-specific alterations at high depth, improving sensitivity for low-level residual disease [ 9 , 16 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Next-generation DNA sequencing
Shendure, J., & Ji, H. (2008) · Nature Biotechnology · doi:10.1038/nbt1486 · Cited by 4,509
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. �., & Pantel, K. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3066 · Cited by 2,897
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Research works printed but not linked: 1
- Pierson-Perry, 2012, Evaluation of detection capability for clinical laboratory measurement procedures: approved guideline
Cited by
Sorted by citations
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Self-citationTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 836
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 726
Self-citationTracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., et al. (2023) · Nature · doi:10.1038/s41586-023-05776-4 · Cited by 382
Gale, D. G., Heider, K., Ruiz-Valdepeñas, A., Hackinger, S., Perry, M., Marsico, G., Rundell, V., Wulff, J., Sharma, G., Knock, H., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.007 · Cited by 352
Pre-metastatic niche: formation, characteristics and therapeutic implication
Wang, Y., Jia, J., Wang, F., Fang, Y., Yang, Y., Zhou, Q., Yuan, W., Gu, X., Hu, J., & Yang, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01937-7 · Cited by 289
Circulating tumor DNA: current challenges for clinical utility
Dang, D. K., & Park, B. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154941 · Cited by 239
Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation
Ren, F., Fei, Q., Qiu, K. L., Zhang, Y., Zhang, H., & Sun, L. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03026-7 · Cited by 178
Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies
Martin-Alonso, C., Tabrizi, S., Xiong, K., Blewett, T., Sridhar, S., Crnjac, A., Patel, S., An, Z., Bekdemir, A., Shea, D., et al. (2024) · Science · doi:10.1126/science.adf2341 · Cited by 158
Tie, J., Wang, Y., Lo, S., Lahouel, K., Cohen, J. D., Wong, R., Shapiro, J. D., Harris, S. J., Khattak, A., Burge, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03579-w · Cited by 159
Bridging biological cfDNA features and machine learning approaches
Moser, T., Kühberger, S., Lazzeri, I., Vlachos, G., & Heitzer, E. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.01.004 · Cited by 133
Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 141
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
Clinical Circulating Tumor DNA Testing for Precision Oncology
Kim, H., & Park, K. U. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1026 · Cited by 121
A clinician’s handbook for using ctDNA throughout the patient journey
Hasenleithner, S. O., & Speicher, M. R. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01551-7 · Cited by 110
Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA
Semenkovich, N. P., Szymanski, J. J., Earland, N. J., Chauhan, P. S., Pellini, B., & Chaudhuri, A. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006284 · Cited by 111
The role of aberrant DNA methylation in cancer initiation and clinical impacts
Geissler, F., Nesic, K., Kondrashova, O., Dobrovic, A., Swisher, E. M., Scott, C. L., & Wakefield, M. J. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220511 · Cited by 112
Cortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 100
Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection
Bruhm, D. C., Vulpescu, N. A., Foda, Z. H., Phallen, J. A., Scharpf, R. B., & Velculescu, V. E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00795-x · Cited by 110
Liquid Biopsy Based on Cell-Free DNA and RNA
Loy, C., Ahmann, L. S., Vlaminck, I. D., & Gu, W. (2024) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110222-111259 · Cited by 86
Han, K. C.-Z., Zou, J., Zhao, Z., Baskurt, Z., Zheng, Y., Barnes, E. A., Croke, J. M., Ferguson, S. E., Fyles, A., Gien, L. T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00954 · Cited by 77
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients
Chauhan, P. S., Shiang, A. L., Alahi, I., Sundby, R. T., Feng, W., Gungoren, B., Nawaf, C., Chen, K. Y., Babbra, R. K., Harris, P. K. W., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-022-00345-w · Cited by 77
The evolving role of liquid biopsy in lung cancer
Malapelle, U., Pisapia, P., Pepe, F., Russo, G., Buono, M., Russo, A., Gomez, J. E., Khorshid, O., Mack, P. C., Rolfo, C. D., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.08.004 · Cited by 77
Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer
Shen, H., Jin, Y., Zhao, H., Wu, M., Zhang, K., Wei, Z., Wang, X., Wang, Z., Li, Y., Yang, F., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02681-x · Cited by 75
Caputo, V., Ciardiello, F., Corte, C. M. D., Martini, G., Troiani, T., & Napolitano, S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00125 · Cited by 80
Jung, H. A., Ku, B. M., Kim, Y. J., Park, S., Sun, J., Lee, S., Ahn, J. S., Cho, J. H., Kim, H. K., Choi, Y. S., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.027 · Cited by 72
Liquid biopsy into the clinics: Current evidence and future perspectives
Boukovala, M. A., Westphalen, C. B., & Probst, V. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100146 · Cited by 77
Shi, W., Wartmann, T., Accuffi, S., Al-Madhi, S., Perrakis, A., Kahlert, C., Link, A., Venerito, M., Keitel, V., Bruns, C. J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02488-4 · Cited by 65
Heidrich, I., Deitert, B., Werner, S., & Pantel, K. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10075-x · Cited by 65
Clinical application of circulating tumour DNA in colorectal cancer
Loft, M., To, Y. H., Gibbs, P., & Tie, J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00146-2 · Cited by 67
Paz-Ares, L. G., Goto, Y., Lim, W., Halmos, B., Cho, B. C., Cobo, M., González-Larriba, J. L., Zhou, C., Demedts, I., Atmaca, A., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2023.107451 · Cited by 63
High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer
Ashley, C. W., Selenica, P., Patel, J., Wu, M. K. Y., Ninčević, J., Lakhman, Y., Zhou, Q. C., Shah, R. H., Berger, M. F., Paula, A. D. C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1134 · Cited by 62
An ultrasensitive method for detection of cell-free RNA
Nesselbush, M. C., Luca, B. A., Jeon, Y.-J., Jabara, I., Meador, C. B., Garofalo, A., Binkley, M. S., Hui, A. B., Erve, I. V. ’., Xu, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08834-1 · Cited by 64
Self-citationAbbosh, C., Hodgson, D., Doherty, G. J., Gale, D. G., Black, J. R., Horn, L., Reis-Filho, J. S., & Swanton, C. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.04.004 · Cited by 63
Zheng, J., Qin, C., Wang, Q., Tian, D., & Chen, Z. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105109 · Cited by 54
Duffy, M. J., & Crown, J. P. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac121 · Cited by 55
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Normanno, N., Morabito, A., Rachiglio, A. M., Sforza, V., Landi, L. M., Bria, E., Delmonte, A., Cappuzzo, F., & Luca, A. D. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00985-w · Cited by 60
Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC
Wu, J., Liu, Z., Huang, T., Wang, Y., Song, M. M., Song, T., Long, G., Zhang, X., Li, X., & Zhang, L. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13357 · Cited by 51
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception
Medford, A. J., Moy, B., Spring, L. M., Hurvitz, S. A., Turner, N. C., & Bardia, A. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0757 · Cited by 52
García-Murillas, I., Cutts, R. J., Walsh-Crestani, G., Phillips, E., Hrebien, S., Dunne, K., Sidhu, K., Daber, R. D., Hubert, B., Graybill, C., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07508-2 · Cited by 48
Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review
Tomasik, B., Skrzypski, M. T., Bieńkowski, M., Dziadziuszko, R., & Jassem, J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-742 · Cited by 48
Wu, L., Zhang, Z., Bai, M., Yan, Y., Yu, J., & Xu, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01139-8 · Cited by 48
Marinello, A., Tagliamento, M., Pagliaro, A., Conci, N., Cella, E., Vasseur, D., Remón, J., Lévy, A., Dall’Olio, F. G., & Besse, B. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102791 · Cited by 46
Liquid biopsies across the cancer care continuum
Landon, B. V., Annapragada, A. V., Niknafs, N., Velculescu, V. E., & Anagnostou, V. (2025) · Nature Medicine · doi:10.1038/s41591-025-04093-9 · Cited by 55
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02849-z · Cited by 47
Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma
Wang, M.-D., Diao, Y., Yao, L., Fan, Z., Wang, K.-C., Wu, H., Gu, L., Xu, J., Li, C., Lv, G., et al. (2024) · iLiver · doi:10.1016/j.iliver.2024.100083 · Cited by 42
Chen, B., Liu, S., Zhu, Y., Wang, R., Cheng, X., Chen, B., Dragomir, M. P., Zhang, Y., Hu, Y., Liu, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46307-7 · Cited by 42
Chen, H., & Zhou, Q. (2023) · Oncology Reports · doi:10.3892/or.2023.8543 · Cited by 44
Li, C., Shao, J., Li, P., Feng, J., Li, J., & Wang, C. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216365 · Cited by 44
Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay
Northcott, J. M., Bartha, G. T., Harris, J., Li, C., Navarro, F. C. P., Pyke, R. M., Hong, M., Zhang, Q., Ma, S., Chen, T. X., et al. (2024) · Oncotarget · doi:10.18632/oncotarget.28565 · Cited by 42
Verschoor, N., Bos, M. K., Hoop, E. O., Martens, J. W. M., Sleijfer, S., Jager, A., & Beije, N. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114159 · Cited by 39
Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA
Naei, V. Y., Bordhan, P., Mirakhorli, F., Khorrami, M., Shrestha, J., Nazari, H., Kulasinghe, A., & Warkiani, M. E. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231192401 · Cited by 38
Network approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
Geng, S., Guo, P., Wang, J., Zhang, Y., Shi, Y., Li, X., Cao, M., Song, Y., Zhang, H., Zhang, Z., et al. (2024) · Advanced Materials · doi:10.1002/adma.202307923 · Cited by 37
Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations
Passaro, A., Mok, T. S. K., Attili, I., Wu, Y.-L. L. C., Tsuboi, M., de Marinis, F., & Peters, S. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0459 · Cited by 36
Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays
Lee, J., Cho, E. H., Kim, B., Hong, J., Kim, Y., Kim, Y., Jang, J., Lee, S., Kong, S., Lee, W., et al. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0389 · Cited by 44
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction
Black, J. R., Karasaki, T., Abbott, C. W., Li, B., Veeriah, S., Bakir, M. A., Liu, W. K., Huebner, A., Martínez‐Ruiz, C., Pawlik, P., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.020 · Cited by 42
Tang, H., Cao, Y., Jian, Y., Li, X., Li, J., Zhang, W., Wan, T., Liu, Z., Tang, W., & Lu, S. (2022) · BioScience Trends · doi:10.5582/bst.2022.01019 · Cited by 35
Wyatt, A. W., Litière, S., Bidard, F., Cabel, L., Dyrskjøt, L., Karlovich, C., Pantel, K., Petrie, J., Philip, R., Andrews, H. S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1883 · Cited by 34
Hata, T., Mizuma, M., Motoi, F., Ohtsuka, H., Nakagawa, K., Morikawa, T., & Unno, M. (2022) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1282 · Cited by 36
Dong, Q., Chen, C., Hu, Y., Zhang, W., Yang, X., Qi, Y., Zhu, C., Chen, X., Shen, X., & Ji, W. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2274123 · Cited by 35
Sanz‐García, E., Zou, J., Avery, L. M., Spreafico, A., Waldron, J. N., Goldstein, D. P., Hansen, A. R., Cho, J., de Almeida, J. R., Hope, A. J., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01272-y · Cited by 33
Verzè, M., Pluchino, M., Leonetti, A., Corianò, M., Bonatti, F., Armillotta, M. P., Perrone, F., Casali, M., Minari, R., & Tiseo, M. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-390 · Cited by 36
Hashimoto, T., Nakamura, Y., Oki, E., Kobayashi, S., Yuda, J., Shibuki, T., Bando, H., & Yoshino, T. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02493-4 · Cited by 32
Jun, S., Shukla, N. A., Durm, G. A., Hui, A. B., Cao, S., Ganti, A. K., Jabbour, S. K., Kunder, C. A., Alizadeh, A. A., Hanna, N. H., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.06.024 · Cited by 34
Self-citationCirculating Tumor DNA Allele Fraction
Bredno, J., Venn, O., Chen, X., Freese, P., & Ofman, J. J. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.07.007 · Cited by 33
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal
Bestvina, C. M., Garassino, M. C., Neal, J. W., Wakelee, H. A., Diehn, M., & Vokes, E. E. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00258 · Cited by 31
Self-citationNext-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?
Stetson, D., Labrousse, P., Russell, H., Shera, D. M., Abbosh, C., Dougherty, B. A., Barrett, J. C., Hodgson, D., & Hadfield, J. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02301 · Cited by 32
Development of new techniques and clinical applications of liquid biopsy in lung cancer management
Chen, K., He, Y., Wang, W., Yuan, X., Carbone, D. P., & Yang, F. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.03.062 · Cited by 31
Nakamura, Y., Kaneva, K., Lo, C., Neems, D. S., Freaney, J. E., Boulos, H., Hyun, S. W., Islam, F., Yamada-Hanff, J., Driessen, T. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2396 · Cited by 33
Syeda, M. M., Long, G. V., Garrett, J. H., Atkinson, V. G., Santinami, M., Schadendorf, D., Hauschild, A., Millward, M., Mandalà, M., Chiarion‐Sileni, V., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00139-1 · Cited by 42
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients
Alba-Bernal, A., Godoy-Ortíz, A., Domínguez-Recio, M. E., López-López, E., Quirós-Ortega, M. E., Sánchez-Martín, V., Roldán-Díaz, M. D., Jiménez-Rodríguez, B., Peralta-Linero, J., Bellagarza-García, E., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00642-6 · Cited by 27
Zhu, J. W., Wong, F., Szymiczek, A., Ene, G. E. V., Zhang, S., May, T., Narod, S. A., Kotsopoulos, J., & Akbari, M. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814388 · Cited by 27
Li, L., Jiang, H., Zeng, B., Wang, X., Bao, Y., Chen, C., Ma, L., & Yuan, J. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117757 · Cited by 30
Wu, X., Chau, Y. F., Bai, H., Zhuang, X., Wang, J., & Duan, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1099304 · Cited by 26
Stereotactic body radiation therapy for spinal metastases: A new standard of care
Sacino, A. N., Chen, H., Sahgal, A., Bettegowda, C., Rhines, L. D., Maralani, P. J., & Redmond, K. J. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noad225 · Cited by 26
Liquid biopsies for the monitoring of gliomas and brain metastases in adults
Dwarshuis, G., Kroon, L. L., Brandsma, D., Noske, D. P., Best, M. G., & Sol, N. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02880-9 · Cited by 26
Lonardi, S., Nimeiri, H. S., Xu, C., Zollinger, D. R., Madison, R. W., Fine, A. D., Gjoerup, O. V., Rasola, C., Angerilli, V., Sharma, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911529 · Cited by 26
Remón, J., Saw, S. P. L., Cortiula, F., Singh, P. K., Menis, J., Mountzios, G., & Hendriks, L. E. L. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1451 · Cited by 26
Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors
Zhao, J., Reuther, J., Scozzaro, K., Hawley, M., Metzger, E., Emery, M., Chen, I., Barbosa, M., Johnson, L., O’Connor, A., et al. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00670-1 · Cited by 29
Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer
Abidoye, O., Ahn, D. H., Borad, M. J., Wu, C., Bekaii‐Saab, T., Chakrabarti, S., & Sonbol, M. B. (2025) · Cells · doi:10.3390/cells14030161 · Cited by 26
Simancas‐Racines, D., Román-Galeano, N. M., Vásquez, J. P., Gavilanes, D. J., Vijayan, R., & Reytor-González, C. (2025) · Biomedicines · doi:10.3390/biomedicines13123073 · Cited by 31
Lebow, E. S., Shaverdian, N., Eichholz, J., Kratochvil, L. B., McCune, M., Murciano‐Goroff, Y. R., Jee, J., Eng, J., Chaft, J. E., Kris, M. G., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1253629 · Cited by 22
Bahrambeigi, V., Lee, J. J., Branchi, V., Rajapakshe, K., Xu, Z., Kui, N., Henry, J. T., Wang, K., Stephens, B. M., Dhebat, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-4070 · Cited by 21
Zhang, M., Yang, H., Fu, T., Meng, M., Feng, Y., Qu, C., Li, Z., Xing, X., Li, W., Ye, M., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13481 · Cited by 21
Alshammari, A. H., Oshiro, T., Ungkulpasvich, U., Yamaguchi, J., Morishita, M., Khdair, S. A., Hatakeyama, H., Hirotsu, T., & di Luccio, E. (2025) · Animals · doi:10.3390/ani15030389 · Cited by 21
Nielsen, L. R., Guldbrandsen, K. F., Ahlborn, L. B., Bloch, M., Skougaard, K., Albrecht‐Beste, E., Nellemann, H. M., Krakauer, M., Gørtz, P. M., Fledelius, J., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108528 · Cited by 21
Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer
Moding, E. J., Esfahani, M. S., Jin, C., Hui, A. B., Nabet, B. Y., Liu, Y., Chabon, J. J., Binkley, M. S., Kurtz, D. M., Hamilton, E. G., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1704 · Cited by 23
Self-citationHIBRID: histology-based risk-stratification with deep learning and ctDNA in colorectal cancer
Loeffler, C. M. L., Bando, H., Sainath, S., Muti, H. S., Jiang, X., van Treeck, M., Reitsam, N. G., Carrero, Z. I., Meneghetti, A. R., Nishikawa, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62910-8 · Cited by 26
Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Earland, N. J., Semenkovich, N. P., Ramirez, R. J., Gerndt, S. P., Harris, P. K. W., Gu, Z., Hearn, A. I., Inkman, M. J., Szymanski, J. J., Whitfield, D., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1789 · Cited by 20
Bui, N. Q., Nemat‐Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., van de Rijn, M., Charville, G. W., Becker, C. R., Wang, D. S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0250 · Cited by 21
Self-citationRemón, J., Lévy, A., Singh, P., Hendriks, L. E. L., Aldea, M. D., & Arrieta, O. G. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221113268 · Cited by 19
Zhou, Y., Wang, R., Zeng, M., & Liu, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1551219 · Cited by 20
Yu, P., Zhu, S., Luo, Y., Li, G., Pu, Y., Cai, B., & Zhang, C. (2022) · Journal of Oncology · doi:10.1155/2022/9635218 · Cited by 18
CD4 T cells and toxicity from immune checkpoint blockade
Earland, N. J., Zhang, W., Usmani, A., Nene, A., Bacchiocchi, A., Chen, D. Y., Sznol, M., Halaban, R., Chaudhuri, A. A., & Newman, A. M. (2023) · Immunological Reviews · doi:10.1111/imr.13248 · Cited by 19
Melton, C. A., Freese, P., Zhou, Y., Shenoy, A., Bagaria, S., Chang, C. C., Kuo, C.-C., Scott, E., Srinivasan, S., Cann, G. M., et al. (2023) · Cancers · doi:10.3390/cancers16010082 · Cited by 22
Cha, Y., Kim, S., & Han, S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.446 · Cited by 17
Yoon, S. M., & Bazan, J. G. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01529-2 · Cited by 17
Hoang, V. N., Nguyen, N. L., Le, D. N., Nguyen, V. S., Thi, H. N., Vu, H. T., Ho, H. H., Le, H. M., Nguyễn, T. D., Vo, H. N., et al. (2025) · JCO oncology advances. · doi:10.1200/oa-24-00084 · Cited by 17
Earland, N. J., Chen, K., Semenkovich, N. P., Chauhan, P. S., Zevallos, J. P., & Chaudhuri, A. A. (2023) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.03.004 · Cited by 15
Metadata
- Authors
- Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Alizadeh, Ash A.
- Diehn, Maximilian
- Venue
- Cancer Discovery
- Published
- 2021-12-01
- Volume
- 11
- Issue
- 12
- Pages
- 2968-2986
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8976700
- OpenAlex
- W3214322235
- Cited by
- 325
- References
- 114
- Citations by year
- 2026: 66 · 2025: 75 · 2024: 74 · 2023: 81 · 2022: 28 · 2021: 1
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (5R25CA180993)
- Postdoctoral Research Fellowship (134031-PF-19-164-01-TBG)
- Leukemia and Lymphoma Society NCI (R01CA257655, R01CA233975, R01CA188298)
- NCI (R01CA188298, R01CA233975, R01CA244526, R01CA254179)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- circulating tumor DNA, minimal residual disease, solid tumors, recurrence prediction, liquid biopsy, adjuvant therapy, treatment response monitoring, liquid biopsy biomarkers, personalized treatment
- MeSH terms
- Circulating Tumor DNA, Humans, Neoplasm Recurrence, Local, Biomarkers, Tumor, Neoplasm, Residual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
